<DOC>
	<DOCNO>NCT01338909</DOCNO>
	<brief_summary>This single-center , randomize , single-blind , investigator-initiated , pharmacological study parallel design . Patients ST elevation myocardial infarction undergo primary percutaneous coronary intervention present high platelet reactivity assess Verify Now P2Y12 assay-Accumetrics ( Platelet Reactivity Units -PRU≥235 ) 2 hour post-clopidogrel 600mg LD ( Day 0 ) , assess Verify Now P2Y12 assay , randomize informed consent , 1:1 ratio follow treatment group : Group Α : Clopidogrel 150mg per day , start Day 1 Day 5 ( 5 day randomization ) Group Β : Prasugrel 60 mg immediate loading ( Day 0 ) follow 10mg/day start Day 1 Day 5 ( 5 day randomization ) . Platelet reactivity assessment perform 2 hour randomization ( Day 0 ) , 24 h randomization ( Day 1 ) Day 5 . Documentation major adverse cardiac event ( death , myocardial infarction , stroke , revascularization procedure PCI CABG ) serious adverse event ( bleed , adverse event ) perform Day 5 .</brief_summary>
	<brief_title>Prasugrel Comparison Clopidogrel Inhibition Platelet Reactivity Patients With ST-elevation Myocardial Infarction ( STEMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Patients STEMI undergo primary PCI stenting 3 . Platelet reactivity PRU ≥235 2 hour post 600 mg clopidogrel load dose 4 . Informed consent obtain write 1 . Treatment investigational agent ( include placebo ) device within 30 day prior randomization plan use investigational agent device prior Day 5 . 2 . Pregnancy 3 . Breastfeeding 4 . Inability give inform consent high likelihood unavailable Day 5 . 5 . Cardiogenic shock 6 . Major periprocedural complication ( death , stent thrombosis , vessel perforation , arrhythmia require cardioversion , temporary pacemaker insertion intravenous antiarrhythmic agent , respiratory failure require intubation , vascular injury ( pseudoaneurysm , arteriovenous shunt , retroperitoneal bleed hematoma &gt; 5 cm arterial catheter insertion site ) , major bleeding ( need bood transfusion drop haemoglobin postPCI ≥ 5 gr/ dl intracranial bleeding ) . 7 . Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; ΤΙΜΙ 3 ) plan stag PCI next 5 day randomization 8 . Requirement oral anticoagulant prior Day 5 9 . Current plan therapy thienopyridine class ADP receptor inhibitor . 10 . Known hypersensitivity prasugrel ticagrelor 11 . History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . 12 . Other bleed diathesis , consider investigator high risk bleed thienopyridine therapy . 13 . Any previous history ischemic stroke , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . 14 . Thrombocytopenia ( &lt; 100.000 / μL ) randomization 15 . Anaemia ( Hct &lt; 30 % ) randomization 16 . Polycythaemia ( Hct &gt; 52 % ) randomization 17 . Periprocedural IIb/IIIa inhibitor administration 18 . Severe allergy contrast agent , unfractionated heparin , enoxaparin bivalirudin adequately premedicated . 19 . Recent ( &lt; 6 week ) major surgery trauma , include GABG . 20 . Subjects receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue duration study . 21 . INR &gt; 1.5 randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>prasugrel</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>primary percutaneous coronary intervention</keyword>
	<keyword>high platelet reactivity</keyword>
</DOC>